GLP-1 Medications and Process Addictions

Over the past few years, medications like Ozempic®, Wegovy®, Mounjaro®, and Zepbound® have transformed the treatment of obesity and type 2 diabetes. Originally developed to regulate blood sugar and appetite, these GLP-1 receptor agonists have produced another unexpected observation: many people report that their cravings for things beyond food seem to diminish as well.

Some individuals have described drinking less alcohol, smoking fewer cigarettes, gambling less, shopping less impulsively, and even experiencing fewer compulsive urges related to repetitive behaviors. While these reports have generated excitement, they have also raised an important question:

Could GLP-1 medications become a treatment for process addictions?

The answer—for now—is maybe. The science is promising, but it's still early.

What Are Process Addictions?

Unlike substance addictions, process (or behavioral) addictions involve behaviors rather than chemicals. These behaviors become reinforcing because they temporarily change how we feel. They may reduce anxiety, relieve boredom, soothe emotional pain, provide excitement, or create a sense of relief or completion.

Examples include:

• Gambling disorder
• Compulsive shopping
• Problematic internet or gaming use
• Compulsive sexual behavior
• Excessive social media use
• Body Focused Process Addictions™ (BFPAs) including Body-Focused Repetitive Behaviors (BFRBs) such as hair pulling and skin picking

Although the behaviors differ, they often share similar brain mechanisms involving reward, reinforcement, habit learning, anticipation, and emotional regulation.

Why Are Researchers Interested in GLP-1 Medications?

GLP-1 receptor agonists were designed to help regulate appetite, but scientists now know that GLP-1 receptors are found not only in the digestive system but also in areas of the brain involved in motivation, reward, and decision-making.

Animal studies suggest these medications may reduce the rewarding effects of addictive substances and decrease compulsive reward-seeking behaviors. Early human studies and observational reports have hinted at similar effects, including reductions in alcohol use and cigarette cravings. Research is now expanding to investigate gambling disorder and other behavioral addictions.

While these findings are encouraging, they do not yet prove that GLP-1 medications are effective treatments for process addictions. Larger, well-controlled clinical trials are still needed.

Could GLP-1s Help People with Body Focused Process Addictions?

This is where the conversation becomes especially interesting.

Many people assume that BFPAs and other body-focused repetitive behaviors are simply "bad habits." In reality, these behaviors are often far more complex.

For many individuals, the behavior serves multiple functions at once. It may regulate difficult emotions, reduce internal tension, satisfy sensory needs, relieve boredom, quiet perfectionistic concerns, or temporarily calm an activated nervous system. Over time, the brain learns that the behavior provides relief, and the cycle becomes increasingly automatic.

If GLP-1 medications reduce the intensity of reward, anticipation, or craving, they could potentially make it easier for some people to interrupt these learned patterns. However, even if urges become less intense, the emotional, sensory, cognitive, and habitual components of the behavior often remain.

In other words, reducing cravings does not automatically teach new coping skills or heal the underlying factors that contributed to the behavior in the first place.

Medication Is Not the Whole Treatment

If future research confirms that GLP-1 medications help reduce compulsive urges, that would represent an exciting addition to treatment—but not a replacement for it.

Most process addictions involve multiple interacting factors, including:

• Emotional regulation difficulties
• Nervous system dysregulation
• Habit learning
• Sensory reinforcement
• Shame
• Perfectionism
• Trauma
• Stress
• Environmental triggers
• Learned coping strategies

Medication may reduce the volume of the urges, but people still benefit from learning healthier ways to respond when difficult emotions arise.

This is why behavioral treatment remains essential.

Approaches such as Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Dialectical Behavior Therapy (DBT), Habit Reversal Training (HRT), Comprehensive Behavioral (ComB) treatment, mindfulness, and trauma-informed care continue to play a central role in helping individuals build lasting recovery.

A Window of Opportunity

One way to think about GLP-1 medications is that they may create a "window of opportunity."

If urges become less frequent or less intense, individuals may have more mental space to practice new coping strategies, build emotional awareness, strengthen nervous system regulation, and develop healthier habits before the old behavior takes over.

Rather than replacing therapy, medication may allow therapy to become even more effective.

What We Still Don't Know

Despite the excitement, there are many unanswered questions.

Researchers are still investigating:

• Which process addictions respond best to GLP-1 medications
• Whether benefits continue after stopping the medication
• Who is most likely to benefit
• How these medications interact with psychotherapy
• The long-term effects on compulsive behaviors
• Whether reductions in urges translate into lasting recovery

These are important questions that deserve careful scientific study.

Looking Ahead

The growing interest in GLP-1 medications reflects a broader shift in how we understand addiction. Rather than viewing compulsive behaviors as failures of willpower, we increasingly recognize them as complex conditions involving learning, reward, emotion, and the nervous system.

That shift is good news.

Whether GLP-1 medications ultimately become part of standard treatment for process addictions remains to be seen. But one thing is already clear: compassionate, evidence-based care that addresses the whole person—not just the behavior—will continue to be the foundation of effective treatment.

As research evolves, GLP-1 medications may become another valuable tool in that process. For some individuals, they may reduce the intensity of urges. For others, they may have little effect. Either way, lasting recovery is about more than suppressing a behavior. It is about understanding the needs that behavior has been meeting, developing healthier ways to meet those needs, and building a life that no longer revolves around the addiction.

That's where real healing begins.